News | August 16, 2025
Cohance Lifesciences reports 13% revenue growth in Q1 FY26
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Subscribe To Our Newsletter & Stay Updated
